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Abstract Interactions of U2 snRNA with anti-Sin precipitable 
proteins in RNA-free cytoplasmic complexes were analyzed. U2 
snRNA was found to bind specifically with proteins in the 6S 
complexes but not in the 20S complexes. The binding activity 
was preserved using U2 snRNA having a mutated Sm binding 
site. Label-transfer experiments indicate that snRNA makes 
direct contact with anti-Sm precipitable proteins in the 6S 
fraction with apparent molecular mass of about 16 kDa. These 
data corroborate that proteins in the 6S core particle are the first 
to interact with snRNA, and suggest that the proteins recognize 
snRNA structures in addition to the Sm site. 
© 1997 Federation of European Biological Societies. 
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1. Introduction 
Small nuclear ribonucleoprotein particles (snRNPs) are 
abundant components of the nucleus which function in 
R N A processing. The four major snRNPs, U l , U2, U5 and 
U4/U6 snRNPs, in conjunction with variety of non-snRNP 
factors, are required for p re -mRNA splicing [1]. These 
snRNPs are composed of an snRNA ( U l , U2, U5 or dimer 
U4/U6), eight common core proteins (B/B', D l , D2, D3 , E, F, 
G) and a varying number of snRNA-specific proteins [2-4]. 
The common core proteins are also known as Sm proteins, 
after Smith, a systemic lupus erythematosus patient whose 
antisera recognizes these proteins [5], and for this reason, 
the snRNAs which complex with the Sm proteins are called 
Sm snRNAs in this study. 
The contacts between the Sm proteins and Sm snRNA are 
not well understood. In vitro cross-linking studies of mature 
nuclear particles indicate that core protein G contacts the 
R N A ' s Sm site, a conserved, single-stranded region 
(PaAU 3 _ 4 NUGPu) found in all Sm snRNAs [6]. The Sm 
site is important to the association of Sm snRNA with mature 
particles [7]. However, snRNA-Sm protein interaction studies 
using snRNAs with mutat ions outside of the Sm site suggest 
that common core proteins make multiple contacts with 
snRNA [8]. 
A model for the cytoplasmic assembly of the snRNAs with 
Sm proteins has been proposed based on the results of in vivo 
kinetic studies [9]. After transcription by R N A polymerase II, 
snRNAs travel to the cytoplasm where they assemble with the 
common core proteins [10,11]. In the cytoplasm, s n R N P pro-
teins are stored in three RNA-free complexes: 2 S-5S (B/B'), 
6S ( D l , D2, E, F , G) and 20S (D3, B/B', 69 kDa) [9,12]. 
Kinetic experiments suggest that the first step in assembly is 
the binding of the snRNA to the 6S complex in the cytoplasm 
'Corresponding author. 
[9-13]. The present study analyzes the specific interaction of 
U2 snRNA, as a representative of the Sm snRNAs, with 
proteins in the cytoplasmic 6S fraction. The in vitro results 
indicate that snRNA make direct contact with proteins in the 
6S fraction which have apparent mobilities similar to D l and 
D2 s n R N P core proteins. 
2. Materials and methods 
2.1. Cell culture 
HeLa cells and murine L929 cells (Tissue Culture Facility, Dept. of 
Microbiology, SUNY at Stony Brook) were maintained as suspension 
cultures in SMEM (Gibco-BRL) supplemented with 7% bovine calf 
serum (Atlanta Biologicals), 2 mM L-glutamine, 100 U/ml penicillin, 
and 100 |ig/ml streptomycin (Gibco-BRL) in a 5% CO2 atmosphere at 
37°C. L929 mouse fibroblast suspension cultures (Tissue Culture Fa-
cility, Dept. of Microbiology, SUNY at Stony Brook) were main-
tained under identical conditions, except that the medium was supple-
mented with 5% bovine calf serum and 2% fetal calf serum (Atlanta 
Biologicals). Cells in suspension culture were maintained between 
4X 105 and 5X 105 cells per ml. 
2.2. Aqueous cytoplasmic fractionation and sedimentation analysis 
Aqueous cytoplasmic extracts for snRNA-Sm protein binding reac-
tions were prepared as previously described [10], except that the buffer 
components differed slightly. HeLa cells (200 ml) were extracted in 
2 ml HKM-Tx buffer (20 mM HEPES [pH 7.9], 100 mM KC1, 3 mM 
MgCl2, 0.5% Triton X-100) with protease inhibitors added. The ex-
tract was resolved on a sucrose gradient containing the same buffer 
minus detergent and 1 ml gradient fractions were collected from the 
top, as described elsewhere [10]. Extracts prepared from HeLa cells 
and from L929 cells had identical RNA-binding activities in the assays 
used in this report (data not shown). 
2.3. In vitro transcription 
Several cDNAs were used as templates for in vitro synthesis of Sm 
snRNAs and 5S RNA with T7 or SP6 RNA polymerase. 32P-labeled 
Sm snRNA was produced by in vitro transcription of linearized plas-
mid templates, as previously described [14]. Plasmid pGEM-U2 for 
transcription of wild-type U2 snRNA, and plasmid pGEM-U2-4 for 
transcription of U2 snRNA with a mutated Sm site, were both pro-
vided by Dr. Thoru Pederson of the Worcester Institute [14]. For 
transcription of human Ul snRAN, the pHUlA vector provided by 
Dr. Jeffrey Patton was used [15]. For transcription of U6 snRNA, T7 
RNA polymerase was used to transcribe 20-50 ng DNA template 
produced by PCR as described [16]. All transcripts were gel purified 
as described [16]. 
To transcribe unlabeled snRNA for use in competition experiments, 
the reaction volume was scaled up 10-fold to yield 200-300 u.g of 
transcript. After transcription, unincorporated nucleotides were re-
moved by passing the sample over a Chroma Spin 30 column (Clon-
tech). The amount of RNA in the eluate was determined by spectro-
photometry. 
2.4. SnRNA-Sm protein binding reaction and non-denaturing gel 
analysis 
For snRNA-Sm protein binding reactions, 15 ul gradient fraction, 
5 ul reaction buffer (10 mM DTT, 2 mM ATP, 100 mM creatine 
kinase, 1 mg/ml tRNA, 0.8 U/ml aprotinin, 4 mM leupeptin, 2 U/ 
ml recombinant RNasin [Promega]), and 1 ng 32P-labeled snRNA 
probe were incubated for 30 min in a 1.5 ml microcentrifuge tube 
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Fig. 1. Gel analysis of co-immunoprecipitation of wild-type U2 
snRNA and of Sm site mutant U2-4 snRNA with Sm precipitable 
proteins from HeLa SI00 extracts (lanes 2,3 and 7,8) and from su-
crose gradient fraction 3 (lanes 4,5 and 9,10). Gel purified 32P-la-
beled wild-type U2 snRNA (lanes 1-5) and 32P-labeled Sm site mu-
tant U2-4 snRNA (lanes 6-10) were used in the binding reactions. 
The migration of full length U2 and U2-4 snRNAs is indicated at 
left by an arrow. (Partial degradation of the RNA occurred during 
immunoprecipitation and subsequent steps which resulted in the ap-
pearance of faster migrating bands.) Uncomplexed wild-type (lane 
1) and mutant (lane 6) U2 snRNAs (0.1 ng) are shown as markers. 
Completed reactions were immunoprecipitated with Y12 Sm mono-
clonal antibody (lanes 2,4,7,9) or with anti-SV40 large T monoclo-
nal antibody (lanes 3,5,8,10). 
at 30°C. 2 |il of loading buffer (50 glycerol, 10 (tg/ml heparin) was 
added to each completed reaction. The reaction samples were run on a 
5% polyacrylamide non-denaturing gel in a buffer with half the con-
centration of TBE (1/2 TBE) [16] and/or UV irradiated for cross-link-
ing analysis (see below). Assembly in S100 extracts was performed as 
described [15]. 
2.5. Co-immunoprecipitation assay 
Reactions to be assayed by immunoprecipitation were scaled up 3-
fold. After an snRNA-Sm protein binding reaction or an assembly 
reaction, the Y12 monoclonal antibody was used to detect RNA-pro-
tein interaction by co-immunoprecipitation. The anti-SV40 T anti-
body was used as a control for non-specific binding during the im-
munoprecipitation. Protein A-Sepharose (50 (il) pre-bound to 
monoclonal antibody was added to each reaction in 1.5 ml micro-
centrifuge tubes and rotated at 4°C for 2 h. Immunoprecipitates 
were washed and displayed on SDS-PAGE gels as previously de-
scribed [10]. 
2.6. Label transfer by UV cross-linking 
RNP complexes formed as described above were also subjected to 
UV light (254 nm) for 8.3 min in a 'Stratalinker' from Stratagene for a 
total of 18 mJ/mm2 [17], immunoprecipitated with a cocktail of three 
anti-Sm mAbs (Y12, 713, and KSm6) which together recognize several 
core proteins [18-20], and then digested with 1 u.g/ml RNase A for 40 
min at 37°C. The sample was boiled in Laemmli protein solubilizing 
solution before analysis by SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) [21]. 
3. Results 
3.1. Co-immunoprecipitation assay for interaction of snRNA 
with proteins in the 6S fraction 
The cytoplasmic distribution of the Sm proteins into 6S and 
20S complexes in sucrose gradient has been demonstrated 
previously [10]. Interaction of Sm snRNAs with cytoplasmic 
Sm proteins from the 6S fraction was assayed by co-immuno-
precipitation of snRNA with Y12 Sm monoclonal antibody 
[18] (Fig. 1). Anti-SV40 T antigen monoclonal antibody was 
used as a control for non-specific interactions during immu-
noprecipitation. For a positive control for assembly, we re-
produced the published s n R N P assembly protocol using HeLa 
SI00 extracts [15]. In vitro transcribed 32P-labeled wild-type 
U2 s n R N A and U2 snRNA with a mutated Sm site (U2-4) 
were compared in parallel assembly reactions. R N A from the 
immunoprecipitations was displayed by SDS-PAGE (Fig. 1). 
The same assay was performed using the SI00 extract and the 
sucrose gradient fraction containing the 6S complex. 
HeLa cell SI00 is an unfractionated cytoplasmic extract, 
Fig. 2. Gel shift analysis of wild-type U2 snRNA and Sm site mutant U2-4 snRNA binding activities across a sucrose gradient. Sucrose gra-
dient fractions in HKM buffer were used to analyze snRNA-Sm protein binding reactions across the gradient. 32P-labeled U2 snRNA was incu-
bated with gradient fractions 2-12 and analyzed on a 5% polyacrylamide non-denaturing gel (A). Identical reactions were performed with 32P-
labeled Sm site mutant U2-4 snRNA (B). Free snRNA was added as marker (lane 1, A,B). Lanes 2-12 indicate gradient fractions 2-12 (A,B). 
Free RNA, complex 1, and complex 2 are indicated. Sedimentation markers are given at the bottom. 
72 M.G. Fury, J. Andersen I FEES Letters 404 (1997) 70-74 
in fractions 3-5 (complex 1), and a weaker activity in fractions 
6-10 (complex 2) (Fig. 2A). A third activity in fractions 10-12 
was not reproducible. U2-4 snRNA yielded a highly similar 
mobility shift pattern (Fig. 2B). Similar patterns of gel mobil-
ity shifts were seen if in vitro synthesized 32P-labeled Ul or 
U4 snRNA were used or if gel purified snRNAs (Ul, U2, U4 
and U5) were isolated from cells labeled with inorganic 
[32P]orthophosphate and used in the analyses (data not 
shown). 
Fig. 3. U2 snRNA specifically competes for RNP complex 1. Cyto-
plasmic extracts were resolved on sucrose gradients. Fraction 4 was 
assayed for U2 snRNA binding activity. Mobility of 32P-labeled U2 
snRNA in a native gel was assayed after incubation with gradient 
buffer alone (lane 1) or with gradient fraction 4 (lane 2). The frac-
tion 4/32P-labeled U2 snRNA binding reaction was performed in the 
presence of increasing amounts of unlabeled U2 snRNA (lanes 3-7) 
or unlabeled U6 snRNA (lanes 8-12) and displayed on the gel. 
Competitor concentrations in ng are given at the top of each lane. 
All reactions were also performed in the presence of 2.5 ug/ml hepa-
rin. Free RNA and complex 1 are indicated at left. 
and contains a pool of snRNP proteins as well as endogenous 
snRNAs. In HeLa S100 extracts, 32P-labeled U2 snRNA in-
teracts with proteins that immunoprecipitate with Y12 mono-
clonal antibody but not with anti-SV40 T antigen monoclonal 
antibody, as expected (Fig. 1, lanes 2,3). After assembly in 
SI00 extracts, the Sm site mutant U2-4 snRNA co-immuno-
precipitates, but at a much reduced level using the Y12 mono-
clonal antibody (Fig. 1, lanes 7,8). The co-immunoprecipita-
tion assay was also used to determine if U2 snRNA interacts 
with anti-Sm-immunoprecipitable proteins in a fraction of su-
crose gradient which has the cytoplasmic 6S complex and no 
detectable levels of snRNAs [10,22]. Y12 monoclonal anti-
body immunoprecipitates low levels of U2, while anti-SV40 
T antigen immunoprecipitation detected nothing (Fig. 1, lanes 
4,5) indicating that U2 snRNA interacts with anti-Sm-precip-
itable proteins in the fraction. In contrast to the S100 results, 
however, the Sm site mutant U2-4 snRNA co-immunoprecip-
itates with anti-Sm-precipitable proteins in the 6S fraction at 
the same level as wild-type U2 snRNA (lanes 9,10). This in-
dicates that anti-Sm precipitable proteins in the snRNA-free 
6S fraction can interact with U2 snRNA independent of the 
Sm site. 
3.3. RNA specificity 
The ability of complexes 1 and 2 to form in the presence of 
a specific competitor (cold U2 snRNA) or a non-specific com-
petitor (cold U6 snRNA) was analyzed. [32P]U2 snRNA was 
incubated with fraction 4 of the sucrose gradient to form only 
complex 1 (see Fig. 3). Complex 1 could be competed out with 
increasing amounts of cold U2 snRNA, but not with increas-
ing amounts of cold U6 snRNA (Fig. 3). Therefore, complex 
1 shows specificity for U2 snRNA. Complex 2 was formed by 
incubation of U2 snRNA with fraction 8. The U2 snRNA or 
U6 snRNA competition for complex 2 did not differ (data not 
shown) suggesting that complex 2 forms from non-specific 
RNA-binding protein(s). 
3.4. Identification of the proteins in the complexes through 
UV cross-linking 
To determine which proteins in the 6S region of the gra-
dient are interacting directly with the snRNAs, in vitro syn-
thesized 32P-labeled U2 snRNA was incubated with an aliquot 
of each gradient fraction, and the samples were UV irradiated 
3.2. Gel mobility shifts 
Nondenaturing gel analysis was used to determine U2 
snRNA-binding activity across all fractions of the HKM su-
crose gradients. In vitro synthesized 32P-labeled U2 and U2-4 
snRNAs were incubated on ice in the presence of excess non-
specific tRNA carrier with a small aliquot of each fraction 
from a sucrose gradient containing unlabeled HeLa cytoplas-
mic proteins. The incubation mixtures were subsequently elec-
trophoresed on non-denaturing polyacrylamide gels at 4°C 
(Fig. 2). Gel shift analysis showed two major binding activities 
for in vitro transcribed human U2 snRNA across the gradient 
fractions (Fig. 2A). There was a strong RNA-binding activity 
Fig. 4. U2 snRNA interacts with Sm precipitable proteins in the 6S 
fraction. 32P-labeled U2 snRNA was incubated with gradient frac-
tions 1-12 across the gradient, subjected to UV radiation, immuno-
precipitated with a cocktail of anti-Sm mAbs containing Y12, 713 
and KSm6, subjected to RNAse and SDS-PAGE. Lanes 1-12 are 
from fractions 1-12, respectively, from the top to the bottom of the 
gradient. Lanes 0~ and 0+ contain U2 snRNA incubated in buffer 
alone without UV radiation (—) and with UV radiation (+). Lane 
M contains snRNP marker proteins immunopreciptiated from 35S-
labeled nuclear extracts made as previously described [12]. The 
snRNP proteins in the marker lane are identified at the left. 
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to cross-link pyrimidine bases to neighboring amino acids in 
the proteins. Cytoplasmic proteins which UV cross-linked to 
the 32P-labeled snRNA were immunoprecipitated with anti-
Sm mAbs. The precipitates were treated with RNase and an-
alyzed by SDS-PAGE (Fig. 4). Three anti-Sm precipitable 
cross-linked species appear in the lanes containing the 6S 
fractions of the sucrose gradient (Fig. 4, lane 3-5). The 
cross-linked species have similar gel mobility (at about 16 
kDa) to the snRNP core proteins Dl and D2 found in the 
6S fraction. Also another cross-linked species was detected 
with an apparent mobility of about 13 kDa. 
As a control for the sensitivity and specificity of the label-
transfer assay, interactions of other small RNAs with proteins 
in the sucrose gradient fractions were also analyzed. 32P-la-
beled U6 snRNA forms a single RNP particle with proteins in 
the 4th fraction of the 6S region of the sucrose gradient (data 
not shown) and cross-links to one protein in that fraction with 
an apparent molecular mass of 45-50 kDa protein (data not 
shown), which almost certainly is La antigen [23]. For com-
parison, 32P-labeled Xenopus 5S rRNA did not cross-link with 
any of the proteins in the gradient (data not shown). The 
results from these two RNAs support the observation that 
complex 1 activity in the 6S fraction has specificity for U2 
snRNA, as representative of the Sm snRNAs. 
4. Discussion 
The present study has examined the interaction of U2 
snRNA with the fractionated cytoplasmic core snRNP pro-
teins using a variety of in vitro approaches. These included 
analyzing the binding of 32P-labeled RNAs to snRNP proteins 
by (1) RNA/protein gel mobility shift analyses, (2) competi-
tion analysis, and (3) label transfer through UV cross-linking 
32P-labeled RNA to protein followed by immunoprecipitation 
of cross-linked proteins after label transfer. Our data suggest 
that the Sm snRNA initially interacts with proteins associated 
with the 6S cytoplasmic snRNP protein complex (Dl, D2, E, 
F, G). 
Analyses by label transfer through UV cross-linking of 32P-
labeled snRNAs to cytoplasmic proteins show that Sm 
snRNAs make direct contact with anti-Sm immunoprecipit-
able proteins in the 6S fractions of the sucrose gradient. The 
cross-linked species have mobility in SDS-PAGE gels similar 
to Dl and D2 core snRNP proteins, which are found in the 
6S fraction. In addition, a smaller 13 kDa cross-linked species 
co-immunoprecipitates with the core snRNP proteins in the 
6S fraction. These in vitro results are consistent with the hy-
pothesis that the first step in snRNP assembly is the interac-
tion of snRNA with proteins in the 6S complex. 
The fact that the cross-linked species are immunoprecipit-
able by anti-Sm monoclonal antibodies, are in the 6S fraction 
and have similar mobilities to Dl and D2 polypeptide sug-
gests that Sm snRNA makes direct contact with Dl and/or 
D2 proteins, however, we have not definitely identified the 
proteins involved. Another laboratory has shown that an im-
munoaffinity-purified sample containing an E/F/G trimer and 
the Dl and D2 proteins results in formation of an snRNP 
subcore particle containing snRNA and Dl , D2, E, F, and G 
[24]. The E/F/G trimer, Dl , and D2 independently assemble 
with the snRNA in the study, however, they do not bind 
snRNA as an intact 6S complex [24]. Heinrichs et al. [6] re-
ported that 32P-labeled snRNAs which contained the Sm-anti-
gen binding motif could be directly cross-linked in situ by UV 
radiation to the snRNP G core protein. Their results indicate 
that the SnRNP G core protein is involved in the recognition 
of the common Sm-antigen binding motif on snRNAs in ma-
ture snRNP particles. Our results do not directly contradict 
this thought, but they open up other possibilities. It may also 
be that at early stages of snRNP assembly, another core pro-
tein is involved in recognition of the Sm snRNA in addition 
to or instead of the G core protein. The core proteins Dl and 
D2 are likely candidates for such recognition. In our hands, 
anti-Sm-immunoprecipitable proteins with mobility of Dl and 
D2 show RNA binding activity when denatured and immobi-
lized on nitrocellulose (data not shown). Others have also 
observed RNA binding activity for Dl under similar condi-
tions [25]. 
The results of the present study indicate that the presence of 
the Sm site, which is essential for mature snRNP particle 
assembly, may be dispensable for the early stages of snRNP 
assembly such as interaction of the Sm proteins in the 6S 
complex with Sm snRNA. Mutation of the Sm site from 
snRNA did not inhibit complex 1 formation although it did 
inhibit snRNP formation with unfractionated S100 extracts. 
The differences between the results from the two extracts may 
be due to the presence of endogenous snRNAs in the SI00 
extract. The Sm site mutant snRNA cannot compete success-
fully with the endogenous wild-type snRNAs in the unfractio-
nated SI00 extract for binding of snRNP proteins since it 
lacks an Sm site. In contrast, without competition, the Sm 
mutant snRNA can bind to the proteins in the 6S fraction, 
which does not have detectable endogenous competitor 
snRNAs [22]. The results suggest then that regions of the 
Sm snRNA other than the Sm site may be important to its 
early interaction with the Sm proteins. This is in agreement 
with other studies which suggest that snRNA sites other than 
the Sm site are involved in interactions with the common core 
proteins [8]. RNA structural elements such as helices have 
been implicated in protein recognition in numerous systems 
and are generally held to be essential for RNA/protein inter-
actions [26]. It is likely that RNA structural elements also play 
some role in Sm snRNA/Sm protein interactions in addition 
to the Sm site. Sm snRNA structures such as helices may be 
involved in early interactions of the RNA with Sm proteins in 
the 6S complexes. 
In summary, this in vitro study indicates that Sm snRNAs, 
in particular U2 snRNA, make direct contact with several 
anti-Sm-immunoprecipitable proteins in the 6S region of a 
sucrose gradient containing fractionated cytoplasmic proteins. 
The proteins have mobilities similar to Dl and D2 snRNP 
core proteins. The initial interaction of the snRNAs with these 
proteins may involve structures on the RNA in addition to the 
Sm site. 
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